

*Application
for
United States Letters Patent*

0989440-070501
T05070"0446860

To all whom it may concern:

Be it known that I, **Cy Stein**,
have invented certain new and useful improvements in

PHOSPHOROTHIOATE ANTISENSE HEPARANASE OLIGONUCLEOTIDES

of which the following is a full, clear and exact description.

PHOSPHOROTHIOATE ANTISENSE HEPARANASE OLIGONUCLEOTIDES

Background of the Invention

5 Heparanase

Cancer is the second leading cause of death in the United States. When cancer has metastasized, it can only be cured by systemic therapy, usually cytotoxic chemotherapy. Alternative methods to prevent tumor spread that would avoid
10 cytotoxic chemotherapy are very desirable.

One area of promise in alternative methods of therapy involves the study of heparanase. Heparanase breaks down heparan - a component of the cell surface and extracellular
15 matrix. It has recently been shown that inhibition of heparanase reduces tumor spread (Kussie, et al. 1999 and Vlodasky, 1999), reducing both tumor neogenesis and angiogenesis.

20 Antisense Phosphorothioate Oligonucleotides

One way to achieve therapeutically useful targeted inhibition of protein expression is likely going to be through the use of antisense oligonucleotides. Antisense
25 oligonucleotides are small fragments of DNA complementary to a defined sequence on a specified mRNA. The antisense oligonucleotide specifically binds to targets on the mRNA molecule and in doing so inhibits the translation of a specific mRNA into protein.

30 Antisense oligonucleotide molecules synthesized with a

phosphorothioate backbone have proven particularly resistant to exonuclease damage compared to standard deoxyribonucleic acids, and so they are used in preference.

- 5 The present study discloses that instead of inhibiting heparanase itself, another method to reduce tumor spread may be to inhibit heparanase protein expression using antisense phosphorothioate oligonucleotides.

10 **Summary of Invention**

This invention provides an oligonucleotide having a sequence complementary to a sequence of a ribonucleic acid encoding a heparanase, wherein:

- 15 (a) the oligonucleotide hybridizes with the ribonucleic acid under conditions of high stringency and is between 10 and 40 nucleotides in length;
- 20 (b) the internucleoside linkages of the oligonucleotide comprise at least one phosphorothioate linkage; and
- 25 (c) hybridization of the oligonucleotide to the ribonucleic acid inhibits expression of the heparanase, wherein inhibition of heparanase expression means at least a 50% reduction in the quantity of heparanase as follows: (a) a T24 bladder carcinoma cell is exposed to a complex of the oligonucleotide and lipofectin at an oligonucleotide concentration of 1 μ M and a lipofectin concentration of 10 μ g/ml for 5 hours
- 30 at 37°C, (b) the complex is completely removed after such exposure, (c) 19 hours later the cell

is scraped, washed and extracted in lysis buffer,
 (d) the nucleus of the cell is removed by
 centrifugation, (e) the cytoplasmic proteins in
 the resulting supernatant are separated according
 5 to mass by sodium dodecyl sulphate polyacrylamide
 gel electrophoresis, (f) the protein is
 transferred to a polyvinylidene difluoride
 membrane that is incubated at room temperature for
 1-2 hours in incubation solution (g) the membrane
 10 is exposed to 1 µg/ml of an antibody directed
 against heparanase at 4°C for 12 hours, (h) the
 membrane is exposed to wash buffer and incubated
 for 1 hour at room temperature in blocking buffer
 comprising a 1:3,000 dilution of a peroxidase-
 15 conjugated secondary antibody directed against an
 epitope on the antibody directed against
 heparanase, (i) the membrane is exposed to a
 chemiluminescent cyclic diacylthydrazide and the
 oxidation of the cyclic diacylthydrazide by the
 20 peroxidase is detected as a chemiluminescent
 signal, and (j) the signal is quantitated by
 laser-scanning densitometry as a measure of the
 amount of heparanase expressed calculated as a
 percentage of heparanase expression in an
 25 untreated cell.

This invention further provides the instant oligonucleotide,
 wherein the oligonucleotide comprises deoxyribonucleotides.

30 This invention further provides the instant oligonucleotide,
 wherein the oligonucleotide comprises ribonucleotides.

This invention further provides the instant oligonucleotide, wherein every internucleoside linkage is a phosphorothioate linkage.

5 This invention further provides the instant oligonucleotide, wherein the oligonucleotide is between 15 and 25 nucleotides in length.

This invention further provides the instant oligonucleotide, wherein the oligonucleotide is about 20 nucleotides in
10 length.

This invention further provides the instant oligonucleotide, wherein the sequence of the oligonucleotide is selected from the following:

15

- (a) CCCCAGGAGCAGCAGCAGCA (SEQ ID NO:3);
- (b) GTCCAGGAGCAACTGAGCAT (SEQ ID NO:4); and
- (c) AGGTGGACTTTCTTAGAAGT (SEQ ID NO:5).

20 This invention further provides the instant oligonucleotide, wherein the oligonucleotide further comprises a modified internucleoside linkage.

This invention further provides the instant oligonucleotide,
25 wherein the modified internucleoside linkage is a peptide-nucleic acid linkage, a morpholino linkage, a phosphodiester linkage or a stereo-regular phosphorothioate.

This invention further provides the instant oligonucleotide,
30 wherein the oligonucleotide further comprises a modified sugar moiety.

This invention further provides the instant oligonucleotide, wherein the modified sugar moiety is 2'-O-alkyl oligoribonucleotide.

- 5 This invention further provides the instant oligonucleotide, wherein the oligonucleotide further comprises a modified nucleobase.

- 10 This invention further provides the instant oligonucleotide, wherein the modified nucleobase is a 5-methyl pyrimidine or a 5-propynyl pyrimidine.

- 15 This invention further provides the instant oligonucleotide, wherein the heparanase is a human heparanase.

- 20 This invention also provides a method of inhibiting expression of a heparanase in a cell comprising contacting the cell with the instant oligonucleotide under conditions such that the oligonucleotide hybridizes with mRNA encoding the heparanase so as to thereby inhibit the expression of the heparanase.

- 25 This invention further provides the instant method, wherein the cell is a cancer cell.

- This invention also provides a composition comprising the instant oligonucleotide in an amount effective to inhibit expression of a heparanase in a cell and a carrier.

- 30 This invention further provides the instant composition, wherein the oligonucleotide and the carrier are capable of passing through a cell membrane.

This invention further provides the instant composition, wherein the carrier comprises a membrane-permeable cationic reagent.

5 This invention further provides the instant composition,
wherein the cationic reagent is lipofectin.

This invention also provides a method of treating a tumor in a subject which comprises administering to the subject an amount of the instant oligonucleotide effective to inhibit expression of a heparanase in the subject and thereby treat the tumor.

This invention further provides the instant method, wherein
15 the subject is a human being.

This invention further provides the instant method, wherein the treatment of the tumor is effected by reducing tumor growth.

This invention further provides the instant method, wherein the treatment of the tumor is effected by reducing tumor metastasis.

25 This invention further provides the instant method, wherein
the treatment of the tumor is effected by reducing
angiogenesis.

30 This invention also provides a method of treating a subject which comprises administering to the subject an amount of the instant oligonucleotide effective to inhibit expression of a heparanase in the subject and thereby treat the

subject.

This invention further provides the instant method, wherein the subject is a human being.

5

This invention also provides the use of the instant oligonucleotide for the preparation of a pharmaceutical composition for treating a tumor in a subject which comprises admixing the oligonucleotide in an amount effective to inhibit expression of a heparanase in the subject, with a pharmaceutical carrier.

This invention also provides an oligonucleotide having a sequence complementary to a sequence of a ribonucleic acid encoding a heparanase, wherein:

- (a) the oligonucleotide hybridizes with the ribonucleic acid under conditions of high stringency and is between 10 and 40 nucleotides in length;
- (b) the internucleoside linkages of the oligonucleotide comprise at least one phosphorothioate linkage; and
- (c) hybridization of the oligonucleotide to the ribonucleic acid inhibits expression of the heparanase.

Brief description of the Figures

5 Figure 1 Western Blot showing reduction of heparanase
protein expression by LB85 (90% compared to
untreated control) and LB90 (95% compared to
control). Also shown are other phosphorothioate
oligonucleotides that were tested but had no
significant effect on heparanase protein
expression.

10

15 Figure 2 Northern blot showing downregulation of heparanase
protein expression by LB85, LB90 and LB65. Also
shown are other phosphorothioate oligonucleotides
that were ineffective at downregulating mRNA
expression as well as the G3DPH control.

Figure 3 This figure shows the DNA sequence encoding Human
heparanase protein.

Detailed Description Of The Invention

The following definitions are presented as an aid in understanding this invention:

5	CDNA	-	Complementary DNA;
	DNA	-	Deoxyribonucleic Acid;
	DTT	-	(-)-1,4-Dithio-L-Threitol;
	ER	-	Endoplasmic Reticulum;
	G3PDH	-	Glycerol-3-Phosphate Dehydrogenase.
10	Hepes	-	N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
	HIV	-	Human Immunodeficiency Virus;
	ICAM- 1	-	Intercellular Adhesion Molecule-1;
	Ig	-	Immunoglobulin;
15	MEM	-	Modified Eagle's Medium
	mRNA	-	Messenger RNA;
	PBS	-	Phosphate Buffered Saline;
	RNA	-	Ribonucleic Acid;
	SDS	-	Sodium Dodecyl Sulphate;
20	SSC	-	Saline-Sodium Citrate Buffer;
	UV	-	Ultra Violet.

"Administer" shall mean any of the various methods and delivery systems known to those skilled in the art. The administering can be performed, for example, orally, via implant, transmucosally, transdermally and subcutaneously.

"Carrier" shall mean any of the various carriers known to those skilled in the art. "Pharmaceutical carrier" shall mean the same, excepting that the carrier shall be pharmaceutically acceptable. In one embodiment, the carrier is a membrane-permeable cationic reagent, preferably

lipofectin. In another embodiment, the carrier is a non-covalently linked peptide complex. In another embodiment the carrier is a covalent linked peptide complex, comprising, for example, a pH sensitive fusogenic peptide. In other
5 embodiments the carriers are polyamidodendrimers; transferrin polylysine; polyglycolic acid co-polymers and any delivery in polymers that can be used to nanoencapsulate, such as polylactic acid. In another
10 embodiment the oligonucleotide is modified by addition of a 5' cholesteryl; and in other embodiments by 5' lipid or alkyl.

The following carriers are set forth, in relation to their most commonly associated delivery systems, by way of
15 example, and do not preclude combinations of carriers.

Dermal delivery systems include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions,
20 lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrrolidone). In one embodiment,
25 the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer. Examples of liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,N_I,N_{II},N_{III}-tetramethyl-N,N_I,N_{II},N_{III}-
30 tetrapalmityl-spermine and dioleoyl phosphatidylethanolamine (DOPE) (GIBCO BRL); (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen

Research); (3) DOTAP (N-[1-(2,3-dioleoyloxy)-N,N,N-tri-
methyl-ammoniummethylsulfate) (Boehringer Mannheim); and (4)
Lipofectamine, 3:1 (M/M) liposome formulation of the
polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO
5 BRL).

Transmucosal delivery systems include patches, tablets,
suppositories, pessaries, gels and creams, and can contain
excipients such as solubilizers and enhancers (e.g.,
10 propylene glycol, bile salts and amino acids), and other
vehicles (e.g., polyethylene glycol, fatty acid esters and
derivatives, and hydrophilic polymers such as
hydroxypropylmethylcellulose and hyaluronic acid).

15 Injectable drug delivery systems include solutions,
suspensions, gels, microspheres and polymeric injectables,
and can comprise excipients such as solubility-altering
agents (e.g., ethanol, propylene glycol and sucrose) and
polymers (e.g., polycaprolactones and PLGA's). Implantable
20 systems include rods and discs, and can contain excipients
such as PLGA and polycaprolactone.

Oral delivery systems include tablets and capsules. These
can contain excipients such as binders (e.g.,
25 hydroxypropylmethylcellulose, polyvinyl pyrrolidone, other
cellulosic materials and starch), diluents (e.g., lactose
and other sugars, starch, dicalcium phosphate and cellulosic
materials), disintegrating agents (e.g., starch polymers and
cellulosic materials) and lubricating agents (e.g.,
30 stearates and talc).

"Blocking buffer" shall mean 5% non-fat milk in phosphate

buffered saline containing 0.5% Tween-20 , wherein Tween-20 is polyoxyethylene(20)sorbitan monolaurate.

5 "Centrifugation" shall mean centrifugation at 8,000 cpm for 10 min. at 4°C.

"Chemiluminescent cyclic diacylthydrazide" shall mean Luminol (Amersham).

10 "Complex" shall mean, when applied to a "complex" of oligonucleotide and lipofectin, a solution comprising Lipofectin diluted in 100 µl of Opti-MEM medium (Gibco BRL) to give a final concentration of 10 µg/ml, and phosphorothioate oligonucleotides diluted in 100 µl of Opti-MEM to give a final concentration of 1 µM mixed gently and
15 preincubated at room temperature for 30 min to allow complexes to form and then diluted with 800 µl of Opti-MEM media.

20 "Extracted in lysis buffer" shall mean exposing cells to 40-50 mL of 10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, 15 µg/ml aprotinin, leupeptin, 50 µg/ml Pefablock SC, 0.5 mM DTT, and 0.3% of Nonidet P40 at 4°C for 10 min.

25 "Heparanase" shall mean the protein encoded by the nucleotide sequence shown in Figure 3 (SEQ ID NO:17) and having the amino acid sequence SEQ ID NO:18, and any variants thereof, whether artificial or naturally occurring.

30 "Incubation solution" shall mean Blotto A (Amersham) [5% bovine serum albumin in phosphate buffered saline containing 0.5% Tween-20, wherein Tween-20 is

polyoxyethylene(20)sorbitan monolaurate.]

"Inhibit" shall mean to slow, stop or otherwise impede.

5 "Modified nucleobase" shall mean, when applied to an
oligonucleotide, nucleotide bases that are substituted or
modified. Apart from the bases of adenine, guanine,
cytosine, and thymine, other natural bases such as inosine,
deoxyinosine, and hypoxanthine are acceptable in the
10 oligonucleotide moiety useful in the subject invention. In
addition, isosteric purine 2'-deoxy-furanoside analogues, 2'-
deoxynebularine or 2'-deoxyxanthosine, or other purine and
pyrimidine analogues such as 5-methyl pyrimidine or a 5-
propynyl pyrimidine may also be used.

15 "Modified sugar" shall mean, when applied to an
oligonucleotide moiety, a sugar modified or replaced so as
to be ribose, glucose, sucrose, or galactose, or any other
sugar. Alternatively, the oligonucleotide may have one or
20 more of its sugars substituted or modified in its 2'
position, i.e. 2'-alkyl or 2'-O-alkyl. An example of a 2'-O-
allyl sugar is a 2'-O-methylribonucleotide. Further, the
oligonucleotide may have one or more of its sugars
substituted or modified to form an α -anomeric sugar.

25 "Oligonucleotide" shall mean an oligonucleotide or
oligodeoxyribonucleotide or an oligoribonucleotide.

"Phosphorothioate", when applied to an oligonucleotide,
30 shall mean an oligonucleotide in which a sulfur atom
replaces one or more of the non-bridging oxygen atoms in one

or more phosphodiester linkages, i.e. an oligonucleotide having one or more phosphorothiodiester linkages. Each phosphorothiodiester linkage can occur as either an Rp or Sp diastereomer. A bridging oxygen atom is an oxygen atom in a phosphodiester linkage of a nucleic acid which joins phosphorous to a sugar.

One or more of the phosphorothiodiester linkages of the oligonucleotide moiety may be modified by replacing one or both of the two bridging oxygen atoms of the linkage with analogues such as -NH, -CH₂, or -S. Other oxygen analogues known in the art may also be used.

A phosphorothioate oligonucleotide may be stereo regular, stereo non-regular or stereo random. A stereo regular phosphorothioate oligonucleotide is a oligonucleotide in which all the phosphodiester linkages or phosphorothiodiester linkages polarize light in the same direction. Each phosphorous in each linkage may be either an Sp or Rp diastereomer. Phosphorothioate oligonucleotides which are created in an automated synthesizer are stereo random which means that each phosphorous atom in the phosphorothioate oligonucleotide has a 50% chance of being either an Sp or an Rp diastereomer.

"Specifically hybridize", when referring to the action of the instant oligonucleotide on a target mRNA molecule, shall mean the annealing of the instant oligonucleotide to the target mRNA molecule, based on sequence complementarity, without annealing to another mRNA molecule lacking a sequence complementary to the instant oligonucleotide. The propensity for hybridization between nucleic acids depends

on the temperature and ionic strength of their milieu, the length of the oligonucleotide and the degree of complementarity. The effect of these parameters on hybridization is well known in the art (see Sambrook, 1989).

5

"Stringent conditions" or "Stringency", shall refer to the conditions for hybridization as defined by the nucleic acid, salt, and temperature. These conditions are well known in the art and may be altered. Numerous equivalent conditions comprising either low or high stringency depend on factors such as the length and nature of the sequence (DNA, RNA, base composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (e.g., formamide, dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature). One or more factors be may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions. As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

25

"Subject" shall mean any animal, such as a human, a primate, a mouse, a rat, a guinea pig or a rabbit.

"Variants" shall mean proteins having at least 80%, preferably at least 90%, more preferably at least 95% similarity with SEQ ID N0:18. As used herein "similar" is used to denote which sequences when aligned have similar

(identical or conservatively substituted) amino acids in like positions or regions, where identical or conservatively replaced amino acids are those which do not alter the activity or function of the protein as compared to the starting protein.

"Wash buffer" shall mean phosphate buffered saline with 0.5% Tween-20, wherein Tween-20 is polyoxyethylene(20)sorbitan monolaurate.

"Washed" shall mean washed in phosphate buffered saline.

Having due regard to the preceding definitions, the present invention provides an oligonucleotide having a sequence complementary to a sequence of a ribonucleic acid encoding a heparanase, wherein:

(a) the oligonucleotide hybridizes with the ribonucleic acid under conditions of high stringency and is between 10 and 40 nucleotides in length;

(b) the internucleoside linkages of the oligonucleotide comprise at least one phosphorothioate linkage; and

(c) hybridization of the oligonucleotide to the ribonucleic acid inhibits expression of the heparanase, wherein inhibition of heparanase expression means at least a 50% reduction in the quantity of heparanase as follows: (a) a T24 bladder carcinoma cell is exposed to a complex of the oligonucleotide and lipofectin at an oligonucleotide concentration of 1 μ M and a lipofectin concentration of 10 μ g/ml for 5 hours

09895440-070501

5 at 37°C, (b) the complex is completely removed
after such exposure, (c) 19 hours later the cell
is scraped, washed and extracted in lysis buffer,
(d) the nucleus of the cell is removed by
centrifugation, (e) the cytoplasmic proteins in
the resulting supernatant are separated according
to mass by sodium dodecyl sulphate polyacrylamide
gel electrophoresis, (f) the protein is
transferred to a polyvinylidene difluoride
10 membrane that is incubated at room temperature
for 1-2 hours in incubation solution (g) the
membrane is exposed to 1 µg/ml of an antibody
directed against heparanase at 4°C for 12 hours,
(h) the membrane is exposed to wash buffer and
15 incubated for 1 hour at room temperature in
blocking buffer comprising a 1:3,000 dilution of
a peroxidase-conjugated secondary antibody
directed against an epitope on the antibody
directed against heparanase, (i) the membrane is
20 exposed to a chemiluminescent cyclic
diacylthydrazide and the oxidation of the cyclic
diacylthydrazide by the peroxidase is detected as
a chemiluminescent signal, and (j) the signal is
quantitated by laser-scanning densitometry as a
25 measure of the amount of heparanase expressed
calculated as a percentage of heparanase
expression in an untreated cell.

In one embodiment every internucleoside linkage is a
phosphorothioate linkage. In one embodiment the ribonucleic
30 acid molecule is a messenger ribonucleic acid molecule. In
a further embodiment the ribonucleic acid molecule encodes

for heparanase protein. In one embodiment the hybridization of the oligonucleotide to the ribonucleic acid molecule inhibits heparanase protein expression. In one embodiment the heparanase protein is human. In one embodiment the oligonucleotide comprises deoxyribonucleotides. In another embodiment the oligonucleotide comprises ribonucleotides. In one embodiment the oligonucleotide sequence is a minimum of 10 and a maximum of 40 nucleobases in length. In another embodiment the oligonucleotide sequence is a minimum of 15 and a maximum of 25 nucleobases in length. In the preferred embodiment the phosphorothioate oligonucleotide is about 20 nucleobases in length.

This invention further provides the instant oligonucleotide, wherein the sequence is selected from the following group:

- (a) CCCAGGAGCAGCAGCAGCA (SEQ ID NO:3);
- (b) GTCCAGGAGCAACTGAGCAT (SEQ ID NO:4); and
- (c) AGGTGGACTTTCTTAGAAGT (SEQ ID NO:5).

In one embodiment hybridization occurs at target residues 137-156 of the instant heparanase mRNA molecule (see SEQ ID NO:17) for SEQ ID NO:3, residues 707-726 for SEQ ID NO:4 and residues 852-871 for SEQ ID NO:5.

0989440-070501
This invention further provides the instant oligonucleotide,
wherein the oligonucleotide further comprises a modified
internucleoside linkage. In different embodiments the
modified internucleoside linkage is a peptide-nucleic acid
5 linkage, a morpholino linkage, a phosphodiester linkage or
a stereo-regular phosphorothioate.

This invention further provides the instant oligonucleotide,
wherein the oligonucleotide further comprises a modified
10 sugar moiety. In one embodiment the modified sugar moiety
is 2'-O-alkyl oligoribonucleotide.

This invention further provides the instant oligonucleotide
sequence, wherein the sequence further comprises a modified
15 nucleobase. In one embodiment the modified nucleobase is a
5-methyl pyrimidine. In one embodiment the modified
nucleobase is a 5-propynyl pyrimidine.

This invention also provides a method of inhibiting
20 expression of a heparanase in a cell comprising contacting
the cell with the instant oligonucleotide under conditions
such that the oligonucleotide hybridizes with mRNA encoding
the heparanase so as to thereby inhibit the expression of
the heparanase. In one embodiment the cell is a mammalian

5 This invention also provides a method of treating a subject which comprises administering to the subject an amount of the instant oligonucleotide effective to inhibit expression of a heparanase in the subject and thereby treat the subject.

10 In one embodiment the subject has an abnormality that is treated by inhibiting heparanase expression. In one embodiment the subject has an abnormality that is treated by inhibiting angiogenesis. In the preferred embodiment the subject is human.

15 This invention also provides the use of the instant oligonucleotide for the preparation of a pharmaceutical composition for treating a tumor in a subject which comprises admixing the oligonucleotide in an amount effective to inhibit expression of a heparanase in the subject, with a pharmaceutical carrier. In the preferred embodiment the subject is human.

20 This invention also provides an oligonucleotide having a sequence complementary to a sequence of a ribonucleic acid encoding a heparanase, wherein:

25 (a) the oligonucleotide hybridizes with the ribonucleic acid under conditions of high stringency and is between 10 and 40 nucleotides in length;

(b) the internucleoside linkages of the oligonucleotide comprise at least one phosphorothioate linkage; and

5 (c) hybridization of the oligonucleotide to the ribonucleic acid inhibits expression of the heparanase. In one embodiment inhibition of heparanase expression means at least a 50% reduction in the quantity of heparanase in particular as follows: (a) a T24 bladder carcinoma cell is exposed to a complex of the
10 oligonucleotide and lipofectin at an oligonucleotide concentration of about 1 μ M and a lipofectin concentration of about 10 μ g/ml for about 5 hours at 37°C, (b) the complex is completely removed after such exposure, (c) about
15 19 hours later the cell is scraped, washed and extracted in lysis buffer, (d) the nucleus of the cell is removed by centrifugation, (e) the cytoplasmic proteins in the resulting supernatant are separated according to mass by sodium dodecyl sulphate polyacrylamide gel electrophoresis, (f)
20 the protein is transferred to a polyvinylidene difluoride membrane that is incubated at room temperature for about 1-2 hours in incubation solution (g) the membrane is exposed to about 1 μ g/ml of an antibody directed against heparanase at 4°C for about 12 hours, (h) the membrane is exposed to wash buffer and incubated for about 1
25 hour at room temperature in blocking buffer comprising a 1:3,000 dilution of a peroxidase-conjugated secondary antibody directed against an epitope on the antibody directed against
30

heparanase, (i) the membrane is exposed to a chemiluminescent cyclic diacylthydrazide and the oxidation of the cyclic diacylthydrazide by the peroxidase is detected as a chemiluminescent signal, and (j) the signal is quantitated by laser-scanning densitometry as a measure of the amount of heparanase expressed calculated as a percentage of heparanase expression in an untreated cell.

The following Experimental Details are set forth to aid in an understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims which follow thereafter.

EXPERIMENTAL DETAILS

Antisense phosphorothioate oligonucleotides inhibit heparanase protein expression: Inhibition of heparanase protein expression by anti-heparanase phosphorothioate oligonucleotides was demonstrated by Western blotting, as is shown in Figure 1. T24 bladder carcinoma cells were treated with the phosphorothioate oligonucleotides complexed with Lipofectin. The optimum concentration of the oligomer was 1 μ M. The optimum concentrations of Lipofectin were 10 and 12.5 μ g/ml. The optimum incubation time of the cells with complexes was 5 h, and expression of heparanase protein was assayed after a further 19 h of incubation in complete media in the absence of complex. The most active sequences were LB 85 (SEQ ID NO:4), 90 (SEQ ID NO:5) and 65 (SEQ ID NO:3). The expression of heparanase protein for LB85, 90 and

65 was reduced by approximately 90, 95 and 75%, respectively (Figure 1). No other oligomers produced any significant reduction in target protein levels.

5 Downregulation of Heparanase protein mRNA by antisense
 heparanase phosphorothioate oligonucleotides: Heparanase
 protein mRNA expression in T24 cells treated with anti-
 heparanase phosphorothioate oligonucleotides was evaluated
 by Northern blotting, using the heparanase cDNA fragment as
10 a probe. The 4.4 and 2.0 kB Heparanase protein mRNA species
 were easily visualized (Figure 2). Significantly, only the
 phosphorothioate oligonucleotides that demonstrated activity
 in the Western blot were active in the Northern blot. None
 of the four control phosphorothioate oligonucleotides (LB78
15 - SEQ ID NO:7, LB88 - SEQ ID NO:8, LB94 - SEQ ID NO:6, LB101
 - SEQ ID NO:9), which were entirely inactive in the Western
 blot, demonstrated any activity vs. the untreated controls
 in the Northern blot. The extent of downregulation for LB90
 (SEQ ID NO:5) was approximately 90%, and for LB65 (SEQ ID
20 NO:3) and LB85 (SEQ ID NO:4) approximately 75% (Figure 2).
 These results confirm the Western analysis, and demonstrate
 that these phosphorothioate oligonucleotides cause a
 sequence specific anti-heparanase effect.

25 The Heparanase protein mRNA blots were then stripped and
 reprobed with a control glycerol-3-phosphate dehydrogenase
 cDNA probe (G3PDH). The data demonstrated essentially equal
 RNA loading in each lane, and no decrease in levels of this
 mRNA species.

30

MATERIALS AND METHODS

Cells: T24 cells were grown at 37°C in a humidified 5% CO₂

incubator in McCoy's 5A medium (Gibco BRL, Grand Island, NY), containing 10% (v/v) heat inactivated (56°C) fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY), supplemented with 25 mM Hepes, 100 units/mL penicillin G sodium and 100 g/mL streptomycin sulfate.

Reagents: Anti-human heparanase mouse monoclonal antibody HP-130 (IgG1 subclass) were obtained from Insight (Rehovot, Israel). Anti-mouse horseradish peroxidase conjugated secondary antibody was from Amersham, Arlington Heights, IL. Lipofectin was purchased from Gibco BRL.

Synthesis of phosphorothioate oligonucleotides: The all-phosphorothioate oligonucleotides used in these studies were synthesized on an Applied Biosystems (Foster City, CA) model 380B DNA synthesizer by standard methods. Sulfurization was performed using tetraethylthiuram disulfide/acetonitrile. Following cleavage from controlled pore glass support, oligodeoxynucleotides were base deblocked in ammonium hydroxide at 60°C for 8 h and purified by reversed-phase HPLC [0.1M triethylammonium bicarbonate /acetonitrile; PRP-1 support]. Oligomers were detritylated in 3% acetic acid and precipitated with 2% lithiumperchlorate/acetone, dissolved in sterile water and reprecipitated as the sodium salt from 1 M NaCl/ethanol. Concentrations of the full length species were determined by UV spectroscopy.

The sequences of the phosphorothioate oligonucleotides used were (5' to 3'):

TGGGCTCACCTGGCTGCTCC	(LB63)	SEQ ID NO:1;
CGCCAGCTGCCGCGCAGCGG	(LB62)	SEQ ID NO:2;

5 CCCCAGGAGCAGCAGCAGCA (LB65) SEQ ID NO:3;
 GTCCAGGAGCAACTGAGCAT (LB85) SEQ ID NO:4;
 AGGTGGACTTTCTTAGAAGT (LB90) SEQ ID NO:5;
 TCAAATAGTAGTGATGCCAT (LB94) SEQ ID NO:6;
 CTTCTCCTCCACATCAGGAG (LB78) SEQ ID NO:7;
 ATTGATGAAAATATCAGCCT (LB88) SEQ ID NO:8;
 TTATCCAGCCACATAAAGCC (LB101) SEQ ID NO:9;
 AGCGCAGGCTTCGAGCGCAG (LB64) SEQ ID NO:10;
 GATAGCCAATAATCAGGTAA (LB105) SEQ ID NO:11;
 10 GGTGCCACCAAACCTCAGGT (LB74) SEQ ID NO:12;
 GAGCCCCAGCGCCCTTTTCT (LB60) SEQ ID NO:13;
 GGAGAACCCAGGAGGATGAG (LB72) SEQ ID NO:14;
 CTACAGAGCTTCTTGAGTAG (LB81) SEQ ID NO:15; and
 TATACCTTGGATTGTCAGTG (LB109) SEQ ID NO:16.

15

Treatment of cells with phosphorothioate oligonucleotide/Lipofectin complexes: Cells were seeded the day before the experiment in 6-well plates at a density of 25 - 30 x 10⁴ cells per well to be 65-70% confluent on the day of the experiment. The transfections were performed in Opti-MEM medium (Gibco BRL) as per the manufacturer's instructions. Lipofectin was diluted in 100 µl of Opti-MEM medium to give a final concentration of 10 or 12.5 µg/ml, and phosphorothioate oligonucleotides were diluted in 100 µl of Opti-MEM to give a final concentration of 1 µM. The solutions were mixed gently and preincubated at room temperature for 30 min to allow complexes to form. Then, 800 µl of Opti-MEM media was added, the solution mixed, and overlaid on the cells that were pre-washed with Opti-MEM. The cells were then incubated at 37°C for 5 h, re-fed with fresh complete media containing 10% FBS (no phosphorothioate oligonucleotide/Lipofectin complexes present), and allowed

to incubate for an additional 19 h before cell lysis and extract preparation.

Western Blot Analysis: Cells treated with phosphorothioate oligonucleotide-lipid complexes were scraped, washed with cold PBS and then extracted in 40-50 mL of 10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, 15 µg/ml aprotinin, leupeptin, 50 µg/ml Pefablock SC, 0.5 mM DTT, and 0.3% of Nonidet-P40 at 4°C for 10 min. The nuclei were removed by centrifugation for 10 min at 4°C, and cytoplasmic protein concentrations in the supernatants were determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA). Aliquots of cytoplasmic extracts, containing 35-40 µg of protein, were resolved by 10% PAGE. Proteins were then transferred to PVDF membranes (Amersham, Arlington Heights, IL), and the filters incubated at room temperature for 1-2 h in Blotto A [5% BSA in PBS containing 0.5% Tween 20]. The filters were then probed with 1 µg/ml of the anti-heparanase antibody in Blotto A at 4°C overnight. After washing in PBS-0.5% Tween 20 buffer (3 x 7 min, room temperature), the filters were incubated for 1 h at room temperature in 5% non-fat milk in PBS containing 0.5% Tween-20 with a 1:3,000 dilution of a peroxidase-conjugated secondary antibody (Amersham). After washing (3 x 10 min), ECL was performed according to the manufacturer's instructions. Protein expression was quantitatively analyzed via laser-scanning densitometry using NIH Image Version 1.61 software. All results were calculated as a percentage of protein expression in treated vs. untreated cells.

Northern Blot Analysis: Total cellular RNA was isolated using TRIZOL Reagent (Gibco BRL). 20-30 µg was resolved on

5 a 1.2% agarose gel containing 1.1% formaldehyde and
transferred to Hybond-N nylon membranes (Amersham). A human
heparanase cDNA probe (kindly provided by Insight, Rehovot,
Israel) was ³²P-radiolabeled with [-³²P]dCTP by random primer
10 labeling using a commercially available kit (Promega)
according to the manufacturer's instructions. The blots were
then hybridized with the cDNA probe in 50% formamide, 5X
SSC, 5X Denhard's solution, 0.5% SDS, 1% dextran sulfate,
and 0.1 mg/ml of salmon sperm DNA overnight at 42°C. The
15 filters were washed at room temperature, twice for 15 min
in 2X SSC and 0.1% SDS, once for 20 min in 1X SSC and 0.1%
SDS, and finally twice for 15 min in 0.1X SSC and 0.1% SDS
at 65°C. The filters were exposed to Kodak X-ray film for
12-48 h with intensifying screens at -70°C, and then
developed. A similar procedure was repeated for the G3PDH
control.

REFERENCES

1. Kussie, P.H. et al. (1999) *Biochem. Biophys. Res. Comm.* 261:183-187.
- 5 2. Lebedeva et al, (2000) *Eur J Pharm Biopharm.* 2000 Jul;50(1):101-19.
3. Sambrook et al., "Molecular Cloning: A Laboratory Manual", Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- 10 4. Vlodasky, I. et al, (1999) *Nature Medicine* 5:793-802.

15